Evaluating how bronchodilators affect lung function in bronchiectasis patients
Evaluating Bronchodilator Response in Patients With Bronchiectasis
NA · Rambam Health Care Campus · NCT05932316
This study is testing if a common lung medication can help people with bronchiectasis breathe better by comparing their lung function before and after using it.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 96 (estimated) |
| Ages | 5 Years and up |
| Sex | All |
| Sponsor | Rambam Health Care Campus (other) |
| Locations | 1 site (Haifa) |
| Trial ID | NCT05932316 on ClinicalTrials.gov |
What this trial studies
This clinical trial aims to assess the bronchodilator response (BDR) in patients diagnosed with bronchiectasis. Participants will undergo a series of spirometry tests to evaluate the effectiveness of bronchodilators, specifically Salbutamol, in improving lung function. The study will compare BDR among different subgroups of bronchiectasis patients and healthy controls, while also identifying demographic and clinical factors associated with positive responses. The findings could clarify the role of bronchodilators in managing bronchiectasis and improve treatment strategies.
Who should consider this trial
Good fit: Ideal candidates for this study are patients with a confirmed diagnosis of bronchiectasis who have not experienced a recent pulmonary exacerbation.
Not a fit: Patients under 5 years of age or those unable to perform spirometry will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to better management and treatment options for patients with bronchiectasis.
How similar studies have performed: While some studies have explored bronchodilator responses in bronchiectasis, this specific approach to evaluating BDR in this patient population is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with bronchiectasis confirmed by CT scan * No recent pulmonary exacerbation as determined by prescription of systemic antibiotics in 7 days prior to BDR testing * No use of long-acting beta agonists (LABA) 12 hours before BDR testing or short acting beta agonist (SABA) 4 hours before testing Exclusion Criteria: * Patients under 5 years of age * Patients incapable to perform proper spirometry
Where this trial is running
Haifa
- Rambam Health Campus — Haifa, Israel (RECRUITING)
Study contacts
- Principal investigator: Mordechai Pollak, MD, MSc — pediatric pulmonology institute, Ruth Rappaport children's hospital, Rambam medical center
- Study coordinator: Mordechai Pollak, MD, MSc
- Email: m_pollak@rambam.health.gov.il
- Phone: +972542388651
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Bronchiectasis, Cystic Fibrosis, Primary Ciliary Dyskinesia, Primary Immune Deficiency, Bronchiolitis Obliterans, Bronchodilator response